Recent News

• 03.25.2025 - Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
• 03.18.2025 - Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
• 03.11.2025 - Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
• 03.04.2025 - Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
• 02.19.2025 - Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
• 01.15.2025 - Alzamend Neuro to Present at the Sequire Investor Summit

Recent Filings

• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.13.2025 - S-3 Registration statement under Securities Act of 1933
• 03.13.2025 - DEF 14A Other definitive proxy statements